March 27, 2007 – Regeneron was up 15% on positive Phase II data from its wet AMD drug; CV Therapeutics gained on news that Ranexa was effective for ischemia; BioCryst fell after putting a hold on the IV formulation of Fodosine; CombinatoRX reported CRx-139 failed a Phase II test for rheumatoid arthritis; the FDA released a mixed assessment on Provenge from Dendreon ahead of an advisory panel meeting; AtheroGenics commented more fully on the failure of AGI-1067 to meet its Phase III trial endpoint; Seattle Genetics and Genetech extended their partnership; Adams Respiratory signed a deal with MonoSolRx to use its thin film technology; Isis Pharma summarized data from three Phase II trials on its cholesterol drug; CuraGen began treating patients in a multiple myeloma trial; Myriad Genetics initiated a Phase II trial of Azixa in patients with melanoma; and Barrier Therapeutics reported positive data from a Phase IIb trial of its oral antifungal. The Centient Biotech 200™ fell 25 points to 3868, a loss of .65%. More details...
